Britta V. B.
- Country
- The Netherlands
- Department
- hemato-oncology
Research Overview
- International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children - Sub-protocol D
- Phase II Evaluation of Safety and Efficacy of Zamtocabtagene Autoleucel in Pediatric Relapsed/Refractory Mature B-Cell Neoplasms with Fludarabine and Cyclophosphamide
- Phase I/II Study of Ruxolitinib and Venetoclax in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma with IL-7R/JAK-STAT Mutations
Data & Insights
Has run more than one trial at 26 of 31 partner sites.
Specializations
Pediatric Hematologic Malignancies
This investigator specializes in treating acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in pediatric patients, with particular focus on high-risk and relapsed/refractory cases.
- B-cell precursor ALL
- T-cell ALL/lymphoma
- Mature B-cell neoplasms
The investigator works with novel therapeutic approaches for CD22-positive malignancies in children aged 1-18 years.
Targeted Therapies
Expertise in developing and implementing targeted therapeutic strategies using innovative agents and combinations.
- MAPK/SRC pathway inhibition
- IL-7R/JAK-STAT pathway targeting
- Immunotherapy approaches
The investigator explores combination treatments including dasatinib, venetoclax, ruxolitinib, and trametinib for refractory conditions.
Advanced Therapeutic Development
Focus on innovative treatment strategies for challenging hematologic conditions.
- CAR-T cell therapy
- Monotherapy approaches
- Combination treatment protocols
The investigator evaluates novel therapeutic agents for patients with specific genetic alterations and treatment-resistant disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.